Mood disorders in restless legs syndrome (Willis-Ekbom disease)
Factors such as heat, light exposure, moisture, improper reconstitution, or rough handling can compromise the integrity of this complex 39-amino-acid triple agonist molecule without overt visual indicators
No individual-level data were involved
if persistent, consult your GP rather than altering dosing time, and report adverse effects via the MHRA Yellow Card scheme
In order to achieve the purpose, the technical scheme provided by the invention is as follows: (1) Preparation of compound 2: arg34GLP-1 (9-37) is taken as a starting material, side chain modification is carried out on 26-Lys of the Arg34GLP-1 (9-37) and the compound 1, acylation coupling reaction is carried out under certain reaction pH conditions, and solid is precipitated by adjusting isoelectric point of reaction liquid after post-treatment to obtain a compound 2
Source: Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity In the OASIS 4 trial, gastrointestinal side effects were reported in 74.0% of people taking oral semaglutide 25mg, compared with 42.2% of people taking placebo